FDA warns Mylan on PR plant violations

The FDA has warned Mylan ($MYL) of "significant violations" of manufacturing rules at a plant in Caguas, Puerto Rico, where inspectors found the drugmaker failed to properly test for product uniformity and didn't fully investigate a batch failure. Report

Suggested Articles

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

To help allay supply chain concerns from the novel coronavirus, Sandoz pledged "stable" pricing on certain generics and antibiotics.